Market overview
The global contract development and manufacturing organization market is worth USD 140 bn in 2026 and is forecast to reach USD 303 bn by 2036, growing at a 8.0% CAGR. United States is the largest country market and Drug substance manufacturing is the largest by service segment.
| Scope | Contract development and manufacturing services for drug makers, covering small-molecule and biologic drug substance and drug product, fill-finish, cell and gene therapy manufacturing and process development. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 130 bn |
| Value 2026 | USD 140 bn |
| Value 2036 | USD 303 bn |
| CAGR 2026-2036 | 8.0% |
| Volume 2026 | 233 thousand batches |
| Volume 2036 | 413 thousand batches |
| Average price 2026 | USD 602,700 per batche |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Contract Development and Manufacturing Organization market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 140 bn |
| 2027 | USD 152 bn |
| 2028 | USD 164 bn |
| 2029 | USD 177 bn |
| 2030 | USD 191 bn |
| 2031 | USD 206 bn |
| 2032 | USD 223 bn |
| 2033 | USD 241 bn |
| 2034 | USD 260 bn |
| 2035 | USD 281 bn |
| 2036 | USD 303 bn |
Contract Development and Manufacturing Organization market segmentation
By service
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Drug substance manufacturing | 46.0% | 44.6% | USD 64.6 bn | 7.7% |
| Drug product and fill-finish | 30.0% | 30.5% | USD 42.1 bn | 8.2% |
| Development and analytical | 16.0% | 17.8% | USD 22.5 bn | 9.2% |
| Packaging and others | 8.0% | 7.1% | USD 11.2 bn | 6.7% |
By molecule
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Small molecules | 52.0% | 41.8% | USD 73.0 bn | 5.7% |
| Biologics | 38.0% | 44.3% | USD 53.4 bn | 9.7% |
| Cell and gene therapy | 5.0% | 9.9% | USD 7.0 bn | 15.6% |
| Others | 5.0% | 4.0% | USD 7.0 bn | 5.7% |
By client type
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Large pharma | 46.0% | 42.0% | USD 64.6 bn | 7.0% |
| Mid and small pharma | 30.0% | 30.0% | USD 42.1 bn | 8.0% |
| Biotech | 24.0% | 28.0% | USD 33.7 bn | 9.7% |
By dose form
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Oral solids | 32.0% | 29.0% | USD 44.9 bn | 6.9% |
| Injectables | 36.0% | 35.0% | USD 50.5 bn | 7.7% |
| Biologics and cell therapy | 32.0% | 36.0% | USD 44.9 bn | 9.3% |
By stage
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Preclinical | 12.0% | 11.0% | USD 16.8 bn | 7.1% |
| Clinical | 30.0% | 29.0% | USD 42.1 bn | 7.6% |
| Commercial | 58.0% | 60.0% | USD 81.4 bn | 8.4% |
Top 25 countries for contract development and manufacturing organization by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 85.5% of 2026 revenue and the 25 countries below together hold 96.1%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 46.3 bn | 33.0% | USD 95.2 bn | 7.5% |
| 2 | China | USD 16.8 bn | 12.0% | USD 41.5 bn | 9.4% |
| 3 | Germany | USD 9.8 bn | 7.0% | USD 19.4 bn | 7.0% |
| 4 | Switzerland | USD 8.4 bn | 6.0% | USD 17.3 bn | 7.5% |
| 5 | India | USD 8.4 bn | 6.0% | USD 22.7 bn | 10.4% |
| 6 | South Korea | USD 7.0 bn | 5.0% | USD 19.1 bn | 10.5% |
| 7 | Ireland | USD 7.0 bn | 5.0% | USD 15.2 bn | 8.0% |
| 8 | Italy | USD 5.6 bn | 4.0% | USD 10.6 bn | 6.6% |
| 9 | France | USD 5.6 bn | 4.0% | USD 10.9 bn | 6.9% |
| 10 | Japan | USD 4.9 bn | 3.5% | USD 9.1 bn | 6.3% |
| 11 | Belgium | USD 2.5 bn | 1.8% | USD 5.0 bn | 7.3% |
| 12 | Netherlands | USD 1.8 bn | 1.3% | USD 3.7 bn | 7.2% |
| 13 | Spain | USD 1.5 bn | 1.1% | USD 3.0 bn | 7.3% |
| 14 | Austria | USD 1.5 bn | 1.0% | USD 2.9 bn | 7.2% |
| 15 | Denmark | USD 1.2 bn | 0.9% | USD 2.4 bn | 7.2% |
| 16 | Sweden | USD 1.1 bn | 0.8% | USD 2.3 bn | 7.3% |
| 17 | Singapore | USD 913 mn | 0.7% | USD 2.1 bn | 8.5% |
| 18 | Brazil | USD 856 mn | 0.6% | USD 1.9 bn | 8.5% |
| 19 | Taiwan | USD 800 mn | 0.6% | USD 1.8 bn | 8.6% |
| 20 | Israel | USD 604 mn | 0.4% | USD 1.2 bn | 7.2% |
| 21 | Poland | USD 562 mn | 0.4% | USD 1.3 bn | 8.5% |
| 22 | Mexico | USD 449 mn | 0.3% | USD 1.0 bn | 8.7% |
| 23 | Canada | USD 435 mn | 0.3% | USD 879 mn | 7.3% |
| 24 | Australia | USD 351 mn | 0.2% | USD 697 mn | 7.1% |
| 25 | Saudi Arabia | USD 281 mn | 0.2% | USD 637 mn | 8.5% |
| Rest of world | USD 5.5 bn | 3.9% | USD 11.2 bn | 7.4% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Lonza
- Samsung Biologics
- Thermo Fisher Scientific (Patheon)
- WuXi Biologics
- Fujifilm Diosynth Biotechnologies
- Catalent
Group 2: Regional and specialist players
- Siegfried
- Recipharm
- Cambrex
- Piramal Pharma Solutions
- Asymchem
- Boehringer Ingelheim BioXcell
- Vetter
- CordenPharma
- Curia
- Aenova
Group 3: Emerging and niche players
- Syngene
- Divi's Laboratories
- Abzena
- AGC Biologics
- Aragen Life Sciences
- Resilience
- Ajinomoto Bio-Pharma Services
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the contract development and manufacturing organization market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 8.0% is calculated from the resulting values.
The market is divided by service, by molecule, by client type, by dose form, by stage. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the contract development and manufacturing organization market?
The global contract development and manufacturing organization market is estimated at USD 130 bn in 2025 and USD 140 bn in 2026.
How fast will the contract development and manufacturing organization market grow?
It is forecast to reach USD 303 bn by 2036, a compound annual growth rate of 8.0% from 2026, an increase of USD 163 bn.
Which country is the largest market for contract development and manufacturing organization?
United States is the largest market by revenue at USD 46.3 bn in 2026, 33.0% of the global total. The three largest countries together hold 52.0%.
Which country is growing fastest?
Among the ten largest markets, South Korea is growing fastest at 10.5% a year from 2026 to 2036.
Which contract development and manufacturing organization segment is largest?
In the by service split, Drug substance manufacturing is the largest segment with 46.0% of 2026 revenue.
Who are the leading contract development and manufacturing organization companies?
Global leaders include Lonza, Samsung Biologics, Thermo Fisher Scientific (Patheon), WuXi Biologics.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Clinical TrialsUSD 118 bn · 7.0% CAGR
- Mail Order PharmacyUSD 172 bn · 7.0% CAGR
- Peptide TherapeuticsUSD 110 bn · 12.0% CAGR
- In Vitro DiagnosticsUSD 108 bn · 5.5% CAGR
- Over the Counter DrugsUSD 184 bn · 5.0% CAGR
- Veterinary HealthUSD 187 bn · 7.0% CAGR
- TelemedicineUSD 103 bn · 13.0% CAGR
- Dietary SupplementUSD 198 bn · 7.0% CAGR
← Continuous Positive Airway Pressure (CPAP) Contract Research Organization →